ES2987020T3 - Fragmento de Nkx3.2 y composición farmacéutica que lo comprende como ingrediente activo - Google Patents

Fragmento de Nkx3.2 y composición farmacéutica que lo comprende como ingrediente activo Download PDF

Info

Publication number
ES2987020T3
ES2987020T3 ES21154441T ES21154441T ES2987020T3 ES 2987020 T3 ES2987020 T3 ES 2987020T3 ES 21154441 T ES21154441 T ES 21154441T ES 21154441 T ES21154441 T ES 21154441T ES 2987020 T3 ES2987020 T3 ES 2987020T3
Authority
ES
Spain
Prior art keywords
arthritis
seq
pharmaceutical composition
fragment
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21154441T
Other languages
English (en)
Spanish (es)
Inventor
Dae-Won Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICM CO Ltd
Original Assignee
ICM CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICM CO Ltd filed Critical ICM CO Ltd
Application granted granted Critical
Publication of ES2987020T3 publication Critical patent/ES2987020T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES21154441T 2016-11-09 2017-11-09 Fragmento de Nkx3.2 y composición farmacéutica que lo comprende como ingrediente activo Active ES2987020T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20160149090 2016-11-09

Publications (1)

Publication Number Publication Date
ES2987020T3 true ES2987020T3 (es) 2024-11-13

Family

ID=62110655

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21154441T Active ES2987020T3 (es) 2016-11-09 2017-11-09 Fragmento de Nkx3.2 y composición farmacéutica que lo comprende como ingrediente activo
ES17868981T Active ES3009014T3 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17868981T Active ES3009014T3 (en) 2016-11-09 2017-11-09 Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient

Country Status (9)

Country Link
US (2) US11235025B2 (enExample)
EP (2) EP3539978B1 (enExample)
JP (2) JP6991593B2 (enExample)
KR (4) KR102049987B1 (enExample)
CN (2) CN110036023B (enExample)
AU (2) AU2017358282C1 (enExample)
CA (1) CA3042186C (enExample)
ES (2) ES2987020T3 (enExample)
WO (1) WO2018088813A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3060947B1 (fr) * 2016-12-28 2025-12-26 Ynsect Procede de traitement d'insectes comprenant la separation des cuticules de la partie molle des insectes puis la separation de la partie molle en trois fractions
CA3112915A1 (en) * 2018-10-19 2020-04-23 Icm Co., Ltd. Pharmaceutical composition for treating retinal diseases, comprising nkx3.2 and fragment thereof as active ingredients
KR102336515B1 (ko) * 2018-10-25 2021-12-07 애니젠 주식회사 부포린 유도체 및 이의 용도
CN112409454B (zh) * 2020-11-04 2022-07-05 青岛农业大学 一种法氏囊七肽及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
BR112012004777A2 (pt) * 2009-09-03 2019-09-24 Genentech Inc métodos para tratar diagnósticar e monitorar artrite reumatoide
WO2011093647A2 (en) * 2010-01-26 2011-08-04 Industry-Academic Cooperation Foundation, Yonsei University Genes implicated in osteoarthritis and use thereof
KR101150900B1 (ko) * 2010-01-26 2012-05-30 연세대학교 산학협력단 퇴행성 관절염 치료 조성물
KR101150990B1 (ko) 2010-06-19 2012-06-13 김유정 슬롯리스 고정자를 갖는 브러시리스 직류 모터
WO2012097057A2 (en) * 2011-01-11 2012-07-19 Tufts University Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
UY35368A (es) * 2013-03-08 2014-10-31 Irm Llc Péptidos y composiciones para el tratamiento de daño articular
CA2915296A1 (en) * 2013-06-11 2015-02-26 Portage Pharmaceuticals Ltd. Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
KR102044530B1 (ko) 2017-04-21 2019-11-14 아이씨엠 주식회사 Nkx3.2 및 이의 단편을 유효성분으로 포함하는 망막질환 치료용 약학적 조성물

Also Published As

Publication number Publication date
JP6991593B2 (ja) 2022-01-12
US11235025B2 (en) 2022-02-01
KR20190126753A (ko) 2019-11-12
US20200188480A1 (en) 2020-06-18
EP3835311C0 (en) 2024-08-28
KR102342171B1 (ko) 2021-12-23
AU2020207879B2 (en) 2021-04-15
CA3042186A1 (en) 2018-05-17
EP3539978A2 (en) 2019-09-18
EP3539978A4 (en) 2020-08-05
JP7055455B2 (ja) 2022-04-18
AU2020207879A1 (en) 2020-08-13
WO2018088813A2 (ko) 2018-05-17
JP2021020962A (ja) 2021-02-18
AU2017358282C1 (en) 2020-11-26
US20190351015A1 (en) 2019-11-21
KR102049987B1 (ko) 2019-11-28
EP3539978C0 (en) 2025-02-26
CA3042186C (en) 2021-06-15
KR20180052104A (ko) 2018-05-17
KR102049978B1 (ko) 2019-11-28
CN110036023A (zh) 2019-07-19
AU2017358282A1 (en) 2019-05-23
US11154590B2 (en) 2021-10-26
EP3539978B1 (en) 2025-02-26
AU2017358282B2 (en) 2020-07-30
JP2019535310A (ja) 2019-12-12
EP3835311B1 (en) 2024-08-28
CN115925865A (zh) 2023-04-07
KR20180052103A (ko) 2018-05-17
KR102340761B1 (ko) 2021-12-21
EP3835311A1 (en) 2021-06-16
WO2018088813A3 (ko) 2018-10-04
WO2018088813A9 (ko) 2018-11-15
KR20200129068A (ko) 2020-11-17
ES3009014T3 (en) 2025-03-25
CN110036023B (zh) 2023-01-10

Similar Documents

Publication Publication Date Title
ES2753264T3 (es) Modelos de cáncer y métodos asociados
ES2748038T3 (es) Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
ES2828505T3 (es) Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos
ES2337890T3 (es) Polipeptidos de fusion actriib y usos de los mismos.
RU2675514C2 (ru) Способы модуляции гомеостаза желчных кислот и лечение расстройств и заболеваний, ассоциированных с желчными кислотами
ES3009014T3 (en) Nkx3.2 fragment and pharmaceutical composition comprising same as active ingredient
BR112021008832A2 (pt) Proteínas de núcleo de mininucleossoma e uso em distribuição de ácido nucleico
JP2022525564A (ja) アンジェルマン症候群を治療するためのベクターおよび方法
US11560412B2 (en) Compositions comprising GRIM-19 therapeutics and methods of use
ES2957688T3 (es) Construcción génica suicida doble e inducible y su uso en terapia génica
US20230190869A1 (en) Peptide inhibitors of guanine nucleotide exchange factor h-1
Kitano et al. EGF domain peptide of Developmentally regulated endothelial locus1 facilitates gene expression of extracellularly applied plasmid DNA